tates confirmative genetic approach to patients with cardiomyopathy [5] [6] [7] . We report the case of a 24-month-old boy with hemizygous LAMP2 mutation who presented with failure to thrive and early-onset of hypertrophic cardiomyopathy (HCMP).
Introduction
Danon disease is a rare X-linked dominant disorder, initially described in two boys presenting with cardiomyopathy, skeletal myopathy, and mental retardation [1] . This disease is caused by mutations in lysosome-associated membrane protein 2 (LAMP2) gene located at Xq24 [2] . Major clinical findings include skeletal and cardiac myopathy, cardiac conduction abnormalities, intellectual difficulties, and retinal involvement [3] . Cardiac involvement is the leading cause of death in patients with Danon disease [4] . Early diagnosis is important for family counseling, but molecular diagnosis is difficult because of genetic heterogeneity of cardiomyopathy. With advances of next-generation sequencing (NGS), massive parallel sequencing of multiple genes facili-tion, there was no evidence of muscle weakness and dysmorphic morphology. His development was normal. Laboratory findings including white blood cell of 10,100/mm 3 , hemoglobin of 13.6 g/ dL, platelets of 360,000/mm 3 , thyrotropin stimulating hormone of 2.05 μIU/mL, and free T4 of 1.54 ng/dL were unremarkable, but elevated levels of aspartate aminotransferase (161 U/L) and alanine aminotransferase (88 U/L) were noted. Viral studies such as hepatitis virus A, hepatitis virus B, hepatitis virus C, EpsteinBarr virus, and cytomegalovirus were negative. Elevated liver enzymes persisted and elevated creatinine kinase (337 U/L) was remarked. So he was referred to the pediatric neurology clinic to evaluate neuromuscular disease.
He had motor grade of 5 in all limbs with normal muscle mass and muscle tone. The deep tendon reflex was normal and there was no Gower's sign. He was able to walk independently in a normal gait. His neurology examination revealed no special findings. Developmental milestones in all categories were not delayed, including gross and fine motor milestones. A harsh grade 2 systolic murmur was denoted on the apex area of left anterior chest with regular heartbeat, therefore he was consulted to the pediatric cardiology clinic. The electrocardiogram showed biventricular hypertrophy with high voltage on every chest lead. Echocardiography showed thickened posterior wall of left ventricle and septum with normal systolic function and diastolic dysfunction (Fig. 1) .
We initially performed metabolic assessment to distinguish inherited metabolic cardiomyopathy including fatty acid oxidation disorders and Pompe disease. However, serum amino acid analysis, urine organic acid analysis, acylcarnitine profiles, and molecular analysis of GAA gene results were all unremarkable. Then, we applied targeted exome sequencing to identify monogenic disorders of congenital cardiomyopathy using the MiSeq platform (Illumina, Inc., San Diego, CA, USA) and the TruSight One Sequencing panel (Illumina, Inc.). This panel contains multiple cardiomyopathy-related genes that have been previously reported to be associated with HCMP; the genes related with sarcomere proteins, the genes related with inherited left ventricular hypertrophy, the genes related with syndromic disease with cardiomyopathy, the genes related with metabolic cardiomyopathy, and the genes related with neuromuscular disorders (Table 1) . Using these analyses, we identified a novel hemizygous for c.692del variant in exon 5 of the LAMP2 gene, resulting in a frameshift mutationp.Thr231Ilefs*11 (Fig. 2) . His mother was not a carrier of the mutation. No retinal abnormalities were detected at ophthalmic examination.
Discussion
This case illustrated the clinical efficacy of targeted exome sequencing in patients with HCMP. Usually, Danon disease is presented with cardiomyopathy, skeletal myopathy and varying degree of intellectual disabilities, however in our case, the patient only manifested with early-onset HCMP. Although this condition is a syndromic disease, it is not easy to approach the diagnosis if only one clinical symptom is developed. Therefore, NGS can be an effective diagnostic tool of HCMP.
Cardiomyopathy in Danon disease is progressive, and it develops early as a hypertrophic phenotype. The age at cardiac presentation of Danon disease varied from infancy to the second decade of life in men, and sudden death may occur in patients with this disease in the second or third decade of life. Also, affected males have learning disability or cognitive problems in 70-100% [3, 4] . Skeletal myopathy is also cardinal feature, which denotes progressive proximal muscle weakness of the shoulders, neck, and legs in 80-90% of males [4] . The therapeutic option for Danon disease was limited, but cardiac transplantation enhances the survival of patients [8] .
Since the outcome of HCMP in childhood varies by its under- Minicore (multicore) myopathy LIM, lin-11, islet-1, mec-3; AMP, adenosine monophosphate; WPW, Wolff-Parkinson-White; LEOPARD, lentigines, electrocardiographic conduction defects, ocular hypertelorism, pulmonary stenosis, abnormalities of genitalia, retardation of growth, and deafness. lying disease and age at diagnosis, early detection and diagnosis is important [9] . HCMP in childhood is genetically heterogeneous with many different genes [10] . It can also manifest systemic features affecting non-cardiac organs. Because of these diverse causes, genetic testing is recommended with high level of evidence along with the metabolic work-up in many guidelines [11, 12] . In previous studies, 40-60% of the cause for HCMP was mainly mutations in cardiac sarcomere protein genes using single gene or multiple panel testing by Sanger sequencing [11, 13, 14] . Traditional method to diagnose Danon disease was to confirm the histological and immunohistochemistry findings, such as vacuolation of muscle fibers and absence of LAMP2 protein, respectively, through the muscle biopsy. Recently, NGS has been an advanced diagnostic tool to evaluate the cause of cardiomyopathy. Not only it reduced the turn-around-time compared to the traditional method, but it also increased the diagnostic yield, and enabled to avoid invasive technique necessary for diagnosis such as skeletal/cardiac muscle biopsy [6, 15] . Recent reports on congenital cardiomyopathy including Danon disease using the NGS method are increasing [7] .
To date, more than 90 different disease-causing mutations have been reported (http://www.hgmd.org). Nonsense and frameshift mutations are common types of mutations resulting truncate the LAMP2 protein. The LAMP2p.Thr231Ilefs*11 variant is a novel frameshift mutation located on topological domain. This variant is not present in 1000Genomes browser (http:// browser.1000genomes.org/), NHLBI ESP Exome Variant Server (http://evs.gs.washington.edu/EVS/) and genome Aggregation Database (gnomAD; http://gnomad.broadinstitute.org/). This variant is classified as pathogenic according to the guideline of the American College of Medical Genetics Laboratory Practice Committee Working Group [16] .
In conclusion, we report a novel mutation in LAMP2 gene and our study indicates that target NGS provides a rapid and highly sensitive screening method for the inherited cardiomyopathy. 
